Takeda Pharmaceutical
NDC Database
Takeda Pharmaceutical
NDC Database
National Drug Code (NDC) records including drug products, NDC numbers, nonproprietary names, dosage forms, strengths, labelers and marketing information.
- Total Records 22
- Latest Marketing Date 2018-02-07
- Data Source FDA
- First Marketing Date 2000-05-01
Company Overview
Social Profiles
Company Snapshot
Takeda Pharmaceutical
1-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 103-8668
Japan
www.takeda.com/ View on MapNDC Records ( 22 records )
Nonproprietary Name
roflumilast
Dosage Form
TABLET
Strength
250 ug/1
Labeler
Takeda GmbH
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ROFLUMILAST
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2018-01-29
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
roflumilast
Dosage Form
TABLET
Strength
500 ug/1
Labeler
Takeda GmbH
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ROFLUMILAST
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2011-02-28
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
efavirenz, emtricitabine, and tenofovir disoproxil fumarate
Dosage Form
TABLET, FILM COATED
Strength
600; 200; 300 mg/1; mg/1; mg/1
Labeler
Takeda GmbH
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2006-07-20
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Colchicine
Dosage Form
TABLET, FILM COATED
Strength
0.6 mg/1
Labeler
Takeda GmbH
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
COLCHICINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2009-09-01
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
TENOFOVIR DISOPROXIL FUMARATE
Dosage Form
TABLET, COATED
Strength
300 mg/1
Labeler
Takeda GmbH
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
TENOFOVIR DISOPROXIL FUMARATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2001-10-26
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
emtricitabine and tenofovir disoproxil fumarate
Dosage Form
TABLET, FILM COATED
Strength
200; 300 mg/1; mg/1
Labeler
Takeda GmbH
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2004-08-02
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
PANTOPRAZOLE SODIUM
Dosage Form
TABLET, DELAYED RELEASE
Strength
40 mg/1
Labeler
Takeda GmbH
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
PANTOPRAZOLE SODIUM
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2000-05-01
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
PANTOPRAZOLE SODIUM
Dosage Form
TABLET, DELAYED RELEASE
Strength
20 mg/1
Labeler
Takeda GmbH
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
PANTOPRAZOLE SODIUM
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2000-05-01
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
PANTOPRAZOLE SODIUM
Dosage Form
INJECTION, POWDER, FOR SOLUTION
Strength
40 mg/10mL
Labeler
Takeda GmbH
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
PANTOPRAZOLE SODIUM
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2013-08-12
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
alogliptin and metformin hydrochloride
Dosage Form
TABLET, FILM COATED
Strength
12.5; 1000 mg/1; mg/1
Labeler
Takeda GmbH
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2013-02-05
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
alogliptin and metformin hydrochloride
Dosage Form
TABLET, FILM COATED
Strength
12.5; 500 mg/1; mg/1
Labeler
Takeda GmbH
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2013-02-05
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
emtricitabine and tenofovir alafenamide fumarate
Dosage Form
TABLET, FILM COATED
Strength
200; 25 mg/1; mg/1
Labeler
Takeda GmbH
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2016-04-04
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Bictegravir sodium, Emtricitabine, and Tenofovir Alafenamide Fumarate
Dosage Form
TABLET
Strength
50; 200; 25 mg/1; mg/1; mg/1
Labeler
Takeda GmbH
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2018-02-07
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
pioglitazone and glimepiride
Dosage Form
TABLET
Strength
2; 30 mg/1; mg/1
Labeler
Takeda GmbH
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2006-07-28
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
pioglitazone and glimepiride
Dosage Form
TABLET
Strength
4; 30 mg/1; mg/1
Labeler
Takeda GmbH
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2006-07-28
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Vortioxetine
Dosage Form
TABLET, FILM COATED
Strength
5 mg/1
Labeler
Takeda GmbH
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
VORTIOXETINE HYDROBROMIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2013-10-02
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Vortioxetine
Dosage Form
TABLET, FILM COATED
Strength
10 mg/1
Labeler
Takeda GmbH
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
VORTIOXETINE HYDROBROMIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2013-10-02
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Vortioxetine
Dosage Form
TABLET, FILM COATED
Strength
20 mg/1
Labeler
Takeda GmbH
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
VORTIOXETINE HYDROBROMIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2013-10-02
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Alogliptin Benzoate and Pioglitazone Hydrochloride
Dosage Form
TABLET, FILM COATED
Strength
12.5; 30 mg/1; mg/1
Labeler
Takeda GmbH
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2012-02-07
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Alogliptin Benzoate and Pioglitazone Hydrochloride
Dosage Form
TABLET, FILM COATED
Strength
25; 15 mg/1; mg/1
Labeler
Takeda GmbH
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2012-02-07
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Alogliptin Benzoate and Pioglitazone Hydrochloride
Dosage Form
TABLET, FILM COATED
Strength
25; 30 mg/1; mg/1
Labeler
Takeda GmbH
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2012-02-07
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Alogliptin Benzoate and Pioglitazone Hydrochloride
Dosage Form
TABLET, FILM COATED
Strength
25; 45 mg/1; mg/1
Labeler
Takeda GmbH
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2012-02-07
End Marketing Date
-
Listing Record Certified Through
2026-12-31
NDC Type Breakdown
22 total- Drug for Further Processing
Official Source
NDC data is based on publicly available National Drug Code information from the U.S. Food and Drug Administration (FDA).
Visit FDA NDC DirectoryNDC Record Details Preview
Explore important National Drug Code information available in the records above.
NDC
47234-0088
Nonproprietary Name
roflumilast
Labeler
Takeda GmbH
Dosage Form
TABLET
FDA NDC Data
National Drug Code information
Regular Updates
Data maintained from official sources
Structured Database
Searchable pharmaceutical data
Reliable Data
Organized NDC records
Create a New Buying Request
Fields marked with * are mandatory.